Johnson & Johnson Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Johnson & Johnson Bundle
See the Bigger Picture
Discover how Johnson & Johnson's diverse product portfolio aligns with the strategic framework of the BCG Matrix. Understand which of their offerings are market leaders and which require careful consideration for future investment.
This glimpse into Johnson & Johnson's BCG Matrix is just the beginning. Unlock the full report to gain detailed quadrant placements, actionable insights, and a clear roadmap for optimizing their product strategy and resource allocation.
Stars
Darzalex (Daratumumab)
Darzalex, a groundbreaking treatment for multiple myeloma, remains a powerhouse within Johnson & Johnson's Innovative Medicine portfolio. In the first quarter of 2025, it achieved an impressive growth rate exceeding 20%, underscoring its sustained market momentum.
The drug's expanding market share across all therapeutic lines highlights its increasing adoption and effectiveness. This robust performance, coupled with ongoing label expansions, firmly cements Darzalex's status as a leading oncology product and a critical contributor to J&J's revenue streams.
Carvykti (Ciltacabtagene Autoleucel)
Carvykti (ciltacabtagene autoleucel), a groundbreaking CAR-T cell therapy for multiple myeloma, stands as a significant growth driver within Johnson & Johnson's portfolio. Its trajectory is marked by robust sales expansion, fueled by ongoing efforts to scale up manufacturing capacity and enhance operational efficiencies. This therapy's 'one-and-done' treatment model, coupled with its proven ability to achieve durable, long-term remissions, positions it for substantial market penetration and solidifies its importance in J&J's oncology offerings.
Tremfya (Guselkumab)
Tremfya, a key immunology product from Johnson & Johnson, is a strong performer in the BCG matrix, categorized as a Star. Its continued success in treating psoriasis and psoriatic arthritis, coupled with expanding indications, fuels its growth. For instance, Johnson & Johnson reported Tremfya sales of $2.6 billion in 2023, a significant increase from the previous year, highlighting its robust market position.
Rybrevant / Lazcluze (Amivantamab / Lazertinib)
Rybrevant/Lazcluze (amivantamab/lazertinib) represents a significant advancement for Johnson & Johnson in the oncology sector, specifically targeting non-small cell lung cancer (NSCLC). This combination therapy is a relatively new entrant but is experiencing rapid growth, indicating its strong market potential.
The product's trajectory is bolstered by impressive clinical developments. Recent data, including overall survival (OS) results, further solidify its efficacy. Furthermore, the potential for a subcutaneous formulation could enhance patient convenience and market accessibility, addressing a critical need in cancer treatment.
With a robust launch and continuous regulatory progress, Rybrevant/Lazcluze is positioned as a future blockbuster product for J&J. Its ability to address a high-need area in NSCLC, coupled with ongoing pipeline enhancements, suggests a strong competitive advantage and substantial revenue generation potential.
- Market Position: Rybrevant/Lazcluze is a new, high-growth product in the NSCLC market.
- Clinical Advancements: Positive overall survival data and a potential subcutaneous formulation are key drivers.
- Revenue Potential: Strong launch and regulatory progress suggest blockbuster status and significant future revenue.
- Strategic Importance: Addresses a critical unmet need in oncology, aligning with J&J's strategic focus.
Abiomed (Impella Heart Pumps)
Abiomed, now part of Johnson & Johnson's MedTech segment following its acquisition in 2024, is positioned as a Star in the BCG Matrix. Its Impella heart pumps are a high-growth product with significant market leadership and robust demand.
The Impella line is a key contributor to MedTech's operational sales growth, demonstrating strong market traction. In 2023, J&J's MedTech segment reported net sales of $27.4 billion, with Abiomed's contribution expected to bolster this further.
- Market Leadership: Impella heart pumps hold a dominant position in the temporary mechanical circulatory support market.
- Growth Driver: The product is a significant contributor to Johnson & Johnson's MedTech segment's sales growth.
- Expanded Potential: A recent FDA expanded indication for pediatric patients broadens the addressable market for Impella devices.
J&J's Stars: High Growth & Market Dominance
Darzalex, Carvykti, Tremfya, Rybrevant/Lazcluze, and Abiomed's Impella heart pumps are all classified as Stars within Johnson & Johnson's BCG Matrix. These products exhibit high market share in rapidly growing sectors, representing significant revenue generators and areas of strategic investment for the company.
Darzalex's performance, exceeding 20% growth in Q1 2025, and Tremfya's $2.6 billion in 2023 sales, exemplify their Star status. Carvykti's scaling manufacturing and Rybrevant/Lazcluze's potential blockbuster trajectory, alongside Abiomed's market leadership in MedTech, further solidify their positions as key growth drivers for Johnson & Johnson.
| Product | Category | Key Growth Drivers | 2023/2025 Data Point |
|---|---|---|---|
| Darzalex | Star | High market share, sustained growth, label expansions | Q1 2025 growth > 20% |
| Carvykti | Star | CAR-T therapy, scaling manufacturing, durable remissions | Focus on operational efficiencies |
| Tremfya | Star | Strong immunology product, expanding indications | 2023 Sales: $2.6 billion |
| Rybrevant/Lazcluze | Star | Rapid growth in NSCLC, positive OS data, potential subcutaneous formulation | Positioned as future blockbuster |
| Abiomed (Impella) | Star | Market leadership in mechanical circulatory support, expanded pediatric indication | Contribution to MedTech's $27.4 billion 2023 net sales |
What is included in the product
Detailed Word Document
Johnson & Johnson's BCG Matrix provides a strategic framework for analyzing its diverse product portfolio, categorizing units into Stars, Cash Cows, Question Marks, and Dogs.
This analysis guides investment decisions, highlighting which J&J business units to invest in, hold, or divest based on market share and growth potential.
Customizable Excel Spreadsheet
The Johnson & Johnson BCG Matrix provides a clear, strategic overview, alleviating the pain of uncertainty about which business units to invest in or divest from.
Cash Cows
Stelara (Ustekinumab)
Stelara, a significant player in the immunology market for conditions like psoriasis and Crohn's disease, has been a consistent revenue generator for Johnson & Johnson. Its established market position and wide range of approved uses have allowed it to maintain strong cash flow.
Despite the anticipated biosimilar entry in the U.S. in 2025, Stelara continues to be a cash cow. J&J's strategic patent management, including agreements for phased biosimilar introductions, aims to mitigate the impact of competition and preserve revenue streams.
Xarelto (Rivaroxaban)
Xarelto (rivaroxaban) has been a cornerstone of Johnson & Johnson's cardiovascular franchise, consistently delivering robust sales. In 2023, J&J reported worldwide Xarelto sales of approximately $4.7 billion, showcasing its significant contribution to the company's revenue.
While Xarelto has navigated patent expirations and a competitive anticoagulant market, its established efficacy and broad physician and patient acceptance have sustained its market position. This continued strong performance solidifies its role as a cash cow, providing stable and substantial profits for Johnson & Johnson.
DePuy Synthes (Orthopaedics)
DePuy Synthes, Johnson & Johnson's orthopaedics division, is a classic cash cow. Its extensive range of surgical and joint reconstruction products taps into a vast and steady market, consistently generating significant revenue for J&J's MedTech segment.
Despite some organizational shifts, DePuy Synthes's entrenched market presence solidifies its role as a dependable source of cash, underpinning its classification as a cash cow within the BCG matrix. For instance, Johnson & Johnson reported MedTech net sales of $27.4 billion in 2023, with orthopaedics being a substantial contributor to this figure.
Ethicon (Surgical Solutions)
Ethicon, a cornerstone of Johnson & Johnson's MedTech business, exemplifies a classic cash cow. Its extensive range of surgical essentials, including sutures and staplers, holds a dominant position in a mature but consistently high-demand market. This strong market share translates into predictable and substantial revenue streams for the company.
These essential surgical tools are indispensable across a wide array of medical procedures, guaranteeing a steady inflow of cash. For instance, Johnson & Johnson's MedTech segment, which includes Ethicon, reported sales of $27.2 billion in 2023, with surgical solutions being a significant contributor. This consistent performance allows Ethicon to generate significant profits without requiring substantial investment for growth.
The robust cash flow generated by Ethicon is crucial, as it provides the financial fuel for innovation and investment in other, potentially faster-growing areas within Johnson & Johnson's broader portfolio. This financial support is vital for maintaining J&J's competitive edge across its diverse healthcare offerings.
- Dominant Market Share: Ethicon commands a leading position in the surgical instruments market.
- Steady Revenue Generation: Essential products ensure consistent sales and predictable cash flow.
- Mature Market: Operates in a stable, well-established sector with ongoing demand.
- Funding for Innovation: Profits are reinvested to support growth in other J&J segments.
Acuvue Contact Lenses (Vision Care)
Acuvue contact lenses, a cornerstone of Johnson & Johnson's Vision segment, represents a classic cash cow. This product line commands a substantial portion of the global contact lens market, a testament to its enduring appeal and effective market penetration. The recurring nature of contact lens purchases, coupled with strong brand loyalty cultivated by Acuvue, ensures a consistent and reliable revenue stream for the company.
In 2024, the global contact lens market was valued at approximately $11.6 billion, with J&J Vision, driven by brands like Acuvue, holding a significant share. This market is characterized by consistent demand, as contact lenses are typically a necessity for wearers, leading to predictable sales cycles.
Key factors contributing to Acuvue's cash cow status include:
- Dominant Market Share: Acuvue consistently ranks among the top brands in the global contact lens market, indicating strong consumer preference and widespread adoption.
- Recurring Revenue Model: The necessity of replacing contact lenses at regular intervals creates a predictable and stable revenue base, minimizing sales volatility.
- Brand Equity and Loyalty: Johnson & Johnson's investment in brand building and product innovation has fostered significant customer loyalty, making Acuvue a preferred choice over competitors.
J&J's Cash Cows: Steady Revenue Streams
The cash cow segment for Johnson & Johnson, often characterized by established products with dominant market share in mature industries, continues to be a significant driver of the company's financial stability. These products, like Stelara and Xarelto, generate substantial and consistent profits with minimal need for reinvestment, providing crucial capital for other ventures.
Johnson & Johnson's MedTech division, particularly DePuy Synthes and Ethicon, also falls into this category. These segments benefit from consistent demand for essential medical devices and surgical supplies, ensuring a reliable revenue stream. The company’s strong performance in these areas, as evidenced by the MedTech segment's overall sales, highlights their cash cow status.
Acuvue contact lenses further solidify J&J's cash cow portfolio. The recurring nature of contact lens purchases, coupled with Acuvue’s strong brand loyalty and market position, creates a predictable and substantial revenue base. This segment contributes significantly to J&J's Vision business, underscoring its importance.
Here's a look at some of Johnson & Johnson's key cash cows and their performance:
| Product/Segment | 2023 Sales (Approx.) | Market Status | Cash Cow Contribution |
|---|---|---|---|
| Stelara | $10.1 billion (Pharmaceuticals) | Immunology (Mature, facing biosimilar entry) | Consistent revenue, patent management mitigates impact. |
| Xarelto | $4.7 billion (Pharmaceuticals) | Cardiovascular (Navigated patent expirations) | Strong efficacy and physician acceptance sustain sales. |
| DePuy Synthes (Orthopaedics) | Part of $27.4 billion (MedTech) | Orthopaedics (Established, steady market) | Entrenched market presence, dependable cash source. |
| Ethicon (Surgical Essentials) | Part of $27.2 billion (MedTech) | Surgical Instruments (Mature, high demand) | Dominant share, predictable cash flow for innovation. |
| Acuvue (Contact Lenses) | Significant share of $11.6 billion (Global Contact Lens Market) | Vision Care (Recurring purchases, brand loyalty) | Predictable revenue, stable sales cycles. |
Delivered as Shown
Johnson & Johnson BCG Matrix
The preview you see is the exact Johnson & Johnson BCG Matrix document you will receive upon purchase, ensuring full transparency and immediate usability. This comprehensive report is professionally designed and analysis-ready, offering valuable strategic insights into J&J's product portfolio. Once purchased, you'll gain access to the complete, unwatermarked file, perfectly formatted for your business planning needs. There are no demo elements or hidden surprises; it's the final, polished report ready for immediate download and application.
Dogs
Remicade (Infliximab)
Remicade, a foundational immunology drug for Johnson & Johnson, has seen its market position weaken considerably. By late 2023, the landscape for Remicade was marked by substantial sales erosion, primarily driven by the increasing availability and adoption of biosimilar alternatives. This shift reflects a broader trend in the pharmaceutical industry where originator biologics face intense pricing pressure once patent exclusivity expires.
Once a star performer, Remicade's market share has been significantly impacted. For instance, in the first nine months of 2023, J&J reported a notable decline in Remicade sales, highlighting the growing competitive pressure. This decline underscores the challenges faced by established drugs in a market that increasingly favors cost-effective biosimilar options.
Johnson & Johnson's strategic direction has pivoted, with less emphasis placed on Remicade. The company is now prioritizing newer, more advanced immunology treatments that offer enhanced efficacy or novel mechanisms of action. This strategic repositioning signals a move towards innovation-driven growth, leaving older, albeit once successful, drugs like Remicade to navigate a more challenging market environment.
Imbruvica (Ibrutinib)
Imbruvica (ibrutinib), a key oncology drug for Johnson & Johnson, is experiencing a downturn. While once a star performer, its sales in the United States have been declining. This is largely due to intense competition from newer, more advanced oral therapies entering the market.
The drug now faces significant challenges in holding onto its market share. As of the first quarter of 2024, Imbruvica's sales showed a noticeable drop compared to previous periods, reflecting the increasing pressure from these newer treatments. This situation necessitates a strategic approach to manage the product's future profitability.
Older Neuroscience Products (Ex-US)
Certain older neuroscience products, especially those marketed outside the United States, have seen their market share decrease. This decline is largely attributed to the loss of patent protection, which has opened the door for generic versions to enter the market.
Products like some paliperidone long-acting injectables, while once important, now contribute a smaller portion to Johnson & Johnson's total revenue. These established treatments are facing ongoing challenges from market dynamics and increased competition.
In response, Johnson & Johnson is strategically reallocating its resources and investment focus. The company is prioritizing the development and promotion of newer neuroscience innovations, such as Spravato, to drive future growth and address unmet patient needs.
Certain Orthopaedics Markets/Product Lines
Johnson & Johnson's MedTech segment has strategically divested from specific orthopaedics markets and product lines that were identified as unprofitable. This move is a clear indication that these particular areas within the orthopaedics business were not meeting performance expectations, likely due to low growth or significant competition.
The rationale behind these exits is to enhance the overall profitability of the MedTech segment by shedding underperforming assets. By doing so, J&J can better allocate resources and focus on more promising areas within its broader healthcare portfolio. For example, in 2023, J&J's MedTech segment reported sales of $28.4 billion, and optimizing product lines is crucial for continued growth.
- Divestment of Underperforming Orthopaedics Assets: J&J has exited specific orthopaedics markets and product lines to improve segment profitability.
- Focus on Portfolio Optimization: This strategic restructuring aims to streamline operations and concentrate on higher-growth, higher-market share areas.
- Impact on MedTech Performance: Such decisions are vital for enhancing the financial health and competitive positioning of the MedTech segment, which contributed significantly to J&J's overall revenue in 2023.
Legacy Products with Limited Growth Potential
Within Johnson & Johnson's extensive portfolio, certain legacy products, particularly in older pharmaceutical segments or less innovative medical device lines, likely represent 'Dogs' in the BCG matrix. These offerings typically exhibit minimal market share and face stagnant or declining growth rates, contributing little to overall revenue or profit.
These products often require ongoing investment for regulatory compliance or basic maintenance, potentially becoming cash traps rather than cash generators. Johnson & Johnson's strategic approach involves a continuous evaluation of its diverse business units to identify and either divest or deprioritize these low-potential assets, thereby optimizing resource allocation towards more promising ventures.
For instance, while specific 'Dog' products aren't publicly detailed, J&J's 2023 annual report indicated a strategic focus on key growth areas like Oncology and Immunology, suggesting a deliberate pruning of less vital segments. The company's portfolio optimization efforts are a constant, aiming to streamline operations and enhance profitability by shedding underperforming or non-core assets.
- Minimal Market Share: These legacy products often hold a very small percentage of their respective markets.
- Low Growth Prospects: The markets for these products are typically mature or declining, offering little opportunity for expansion.
- Negligible Cash Generation: They contribute very little financially, and in some cases, may even require more investment than they return.
- Portfolio Optimization: J&J actively reviews and divests such assets to focus on higher-growth, higher-return areas.
Dogs in the BCG Matrix: J&J's Strategic Pruning
Products categorized as Dogs in Johnson & Johnson's BCG matrix are those with low market share and low market growth. These are often older products that have been overtaken by newer innovations or face intense competition from generics and biosimilars.
Johnson & Johnson actively manages its portfolio to identify and address these 'Dog' products. The strategy typically involves either divestment or a minimal investment approach to harvest any remaining value without significant further capital expenditure.
This strategic pruning allows J&J to reallocate resources towards its Stars and Cash Cows, ensuring continued growth and profitability. For example, the company's focus on key therapeutic areas like oncology and immunology in its 2023 reporting suggests a deliberate shift away from less promising legacy products.
The divestment of certain orthopaedics product lines within the MedTech segment in 2023, as mentioned previously, exemplifies this approach to shedding underperforming assets that would otherwise be classified as Dogs.
Question Marks
OTTAVA (General Surgery Robotic System)
OTTAVA, Johnson & Johnson's new general surgery robotic system, is positioned as a question mark in the BCG matrix. Currently undergoing clinical trials, it represents an investment in a high-growth market: robotic surgery. The global robotic surgery market was valued at approximately USD 6.4 billion in 2023 and is projected to reach over USD 15 billion by 2030, indicating substantial expansion.
As an emerging technology, OTTAVA has significant future potential but currently commands a low market share. J&J's substantial investment in its development and upcoming launch aims to secure a leading position in this competitive landscape, aiming to transform it from a question mark into a star performer.
TAR-200 (Bladder Cancer Therapy)
TAR-200, a significant oncology candidate, is currently under priority review by the FDA for bladder cancer treatment. This therapy showcases impressive clinical trial results, particularly in achieving high disease-free survival rates, addressing a critical unmet medical need in the oncology sector.
Given its nascent market presence but substantial growth potential, TAR-200 fits the profile of a Question Mark within the BCG Matrix. This classification signifies its position as a high-potential but unproven product, demanding considerable investment to navigate regulatory hurdles and achieve market penetration.
IMAAVY (Nipocalimab)
IMAAVY, also known as nipocalimab, represents Johnson & Johnson's foray into a significant unmet medical need within the immunology space. As the first FDA-approved FcRn blocker for generalized myasthenia gravis, its recent launch positions it as a promising candidate.
In the context of the BCG Matrix, IMAAVY is currently categorized as a Question Mark. This classification stems from its status as a recently launched product in a high-growth market, demonstrating early traction but still needing substantial investment to solidify its market share and reach its full potential.
The drug's potential is further amplified by its applicability to expanded indications beyond generalized myasthenia gravis, suggesting a broader market opportunity. Johnson & Johnson's strategic focus will be on nurturing IMAAVY's growth, aiming to transform it into a future Star product.
Icotrokinra (Psoriasis)
Icotrokinra, a promising new treatment for psoriasis, is currently in Johnson & Johnson's development pipeline, with Phase III studies underway. This positions it as a potential future Star within the BCG matrix, given the high growth potential of the psoriasis market. As of early 2024, the global psoriasis market was valued at approximately $25 billion and is projected to grow at a CAGR of over 7% through 2030, driven by increasing prevalence and advancements in biologic therapies.
Despite its promising outlook, Icotrokinra currently holds no market share, reflecting its developmental stage. Johnson & Johnson's significant investment in research and development for this product underscores the company's strategic focus on capturing a substantial portion of this expanding market. The success of its ongoing clinical trials and subsequent regulatory approvals will be critical in determining its transition from a question mark to a market leader.
- Icotrokinra's status: Novel psoriasis treatment in J&J's pipeline, undergoing Phase III trials.
- Market context: Psoriasis market is high-growth, valued at ~$25 billion in early 2024, with projected CAGR >7%.
- Current market share: Zero, as the product is still in development.
- Future potential: Success in clinical trials and regulatory approvals could elevate it to a Star, requiring continued R&D investment.
RPGR Gene Therapy (Retinitis Pigmentosa)
The RPGR gene therapy for Retinitis Pigmentosa is a prime example of a Question Mark within Johnson & Johnson's portfolio. This innovative ophthalmology asset is positioned in an area of significant growth and technological advancement, but it currently holds no market share as it remains in early clinical development.
The inherent nature of gene therapies means substantial research and development investment is necessary to navigate the complex clinical trial process and regulatory approvals. This high-risk, high-reward profile is characteristic of Question Marks, where success could lead to a significant market position, but failure or delays could result in considerable R&D write-offs.
- Early Stage Development: RPGR gene therapy is currently in preclinical or early clinical trial phases, indicating significant future investment is required.
- High Growth Potential: The gene therapy market, particularly for rare genetic disorders like Retinitis Pigmentosa, is projected for substantial growth, with some estimates suggesting a compound annual growth rate exceeding 20% in the coming years.
- No Current Market Share: As an unapproved asset, it contributes no revenue and has no established market position.
- Significant R&D Investment: Developing gene therapies is notoriously capital-intensive, demanding substantial funding for research, manufacturing, and clinical trials.
High-Growth Bets: The Question Marks
Question Marks in Johnson & Johnson's portfolio represent products with high growth potential but currently low market share, requiring significant investment to succeed. These are often new technologies or therapies in early development stages. Their future success hinges on navigating clinical trials, regulatory approvals, and market adoption, aiming to transition into Star products.
| Product | Category | Market Growth | Current Market Share | Investment Focus |
| OTTAVA (Robotic System) | Question Mark | High (USD 6.4B in 2023, projected >USD 15B by 2030) | Low (Undergoing trials) | Securing leading position in robotic surgery |
| TAR-200 (Oncology) | Question Mark | High (Oncology market growth) | Low (Nascent presence) | Market penetration and regulatory approval |
| IMAAVY (Immunology) | Question Mark | High (Immunology space) | Low (Recently launched) | Solidifying market share and expanding indications |
| Icotrokinra (Psoriasis) | Question Mark | High (~$25B in early 2024, CAGR >7%) | Zero (In development) | Capturing market share through R&D |
| RPGR Gene Therapy | Question Mark | Very High (Gene therapy market >20% CAGR) | Zero (Early clinical development) | Navigating complex R&D and regulatory pathways |
BCG Matrix Data Sources
Our BCG Matrix is built on verified market intelligence, combining financial data, industry research, official reports, and expert commentary to ensure reliable, high-impact insights.
